6-Fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine] | 741683-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-Fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine]
• 英文别名: 6-fluorospiro[1H-furo[3,4-c]pyridine-3,4'-piperidine]
• CAS: 741683-18-1
• 化学式: C₁₁H₁₃FN₂O
• 分子量: 208.235
• InChiKey: KXZBTFYGGRLKFY-UHFFFAOYSA-N

物化性质

• 沸点：
  334.0±42.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-Fluoro-1H-spiro[furo[3,4-c]pyridine-3,4'-piperidine] 、 3-[tert-butoxycarbonyl(methyl)amino]propyl methanesulfonate 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 tert-butyl [N-methyl-N-[3-(5-fluoro-6-azaisobenzofuran-1(3H)-4'-piperidin)-1-yl]propyl]carbamate
  参考文献：
  名称：

  Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists

  摘要：

  Optimization of high-throughput screening hit 1a led to the identification of a novel spiro-piperidine class of melanin-concentrating hormone 1 receptor (MCH-1R) antagonists. Compound 3c was identified as a highly potent and selective MCH-1R antagonist, which has an IC50 value of 0.09 nM at hMCH-1R. The synthesis and structure-activity relationships of the novel spiro-piperidine MCH-1R antagonists are described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.016

文献信息

• [EN] DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM<br/>[FR] DÉRIVÉ DE DIARYLMÉTHYLAMIDE PRÉSENTANT UNE ACTIVITÉ D'ANTAGONISTE DES RÉCEPTEURS DE L'HORMONE DE MÉLANO-CONCENTRATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2011037771A1

  公开（公告）日：2011-03-31

  The present invention is directed to diarylmethylamide derivatives represented of structural formula I which are melanin-concentrating hormone receptor antagonists, and are useful as an agent for the prevention, treatment, or remedy of various circulatory diseases, neurological diseases, metabolic diseases, reproductive system diseases, respiratory diseases, digestive diseases, and the like. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the melanin-concentrating hormone is involved. I

  本发明涉及结构式I所代表的二芳基甲酰胺衍生物，其为黑色素浓集激素受体拮抗剂，并且可用作预防、治疗或缓解各种循环系统疾病、神经系统疾病、代谢性疾病、生殖系统疾病、呼吸系统疾病、消化系统疾病等的药物。该发明还涉及包含这些化合物的药物组合物以及在黑色素浓集激素参与的这些疾病的预防或治疗中使用这些化合物和组合物。
• NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
  申请人：OHKOUCHI Munetaka

  公开号：US20120277150A1

  公开（公告）日：2012-11-01

  [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.

  提供一种包含GPR40激活剂的药剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、该化合物或盐的溶剂化合物等，特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药物。解决问题的方法是使用式(I)的化合物：（其中p为0至4；j为0至2；k为0至1；环A为芳基、杂环基、环烷基、环烯基、螺环基；环B为芳基、杂芳基；X为0或-NR7-；R1至R7和L为特定基团），该化合物的盐或该化合物或盐的溶剂化合物。
• Diaryl ketimine derivative
  申请人：Ando Makoto

  公开号：US20090247560A1

  公开（公告）日：2009-10-01

  Provided is a compound of a formula (I): [wherein R 1a and R 1b are the same or different, representing a hydrogen atom, etc.; R 2a and R 2b are the same or different, representing a hydrogen atom, etc., or R 2a and R 2b , taken together, form —CH 2 CH 2 —, R 3a and R 3b are the same or different, representing a hydrogen atom, etc.; or R 3a and R 3b , taken together, form —CH 2 CH 2 -etc.; Y 1 and Y 2 represent —C(R) 2 —, etc.; Z represents OR, NR 2 , etc.; R represents a hydrogen atom, a C 1-6 alkyl group, etc.; Ar 1 represents a 6-membered aromatic carbocyclic group, etc.; Ar 2 represents a 6-membered aromatic carbocyclic group, etc; A 3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.

  提供的是化合物公式(I)的复合物：[其中R1a和R1b相同或不同，代表氢原子等；R2a和R2b相同或不同，代表氢原子等，或者R2a和R2b结合形成-CH2CH2-，R3a和R3b相同或不同，代表氢原子等；或者R3a和R3b结合形成-CH2CH2-等；Y1和Y2代表-C(R)2-等；Z代表OR、NR2等；R代表氢原子、C1-6烷基等；Ar1代表6-成员芳香环烷基等；Ar2代表6-成员芳香环烷基等；A3代表6-成员芳香环烷基等。]该化合物可用作治疗中枢障碍、心血管障碍、代谢障碍的药物。
• CYCLIC AMIDE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20140057871A1

  公开（公告）日：2014-02-27

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like. [Means of solving the problem] A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; h is 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J 1a is —CR 11a —, N; J 2 is —CR 12a R 12b —, —CR 12c —; T is —CH 2 —, O, —S(O) i — (i is an integer of 0 to 2) or —NR 7 —; X is O, S, or —NR 7 —; ring A′″ is a benzene ring, a pyridine ring; ring B′ is a benzene ring, a pyridine ring, a pyrimidine ring; and R 1 to R 14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  [问题]提供一种GPR40激活剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、盐或化合物的溶剂化物等，特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症等的药物。[解决问题的方法]化合物的式子为(III):(其中f为0到2；g为1到4；j为0到3；k为0到2；n为0到2；p为0到4；h为0到3；q1为0到3；q2为0或1；r1为0到2(条件是q1 + q2 + r1为0到5)；J1a是—CR11a—，N；J2是—CR12aR12b—，—CR12c—；T是—CH2—、O、—S(O)i—(i为0到2的整数)或—NR7—；X是O、S或—NR7—；环A'″是苯环、吡啶环；环B'是苯环、吡啶环、嘧啶环；R1到R14是特定的基团），该化合物的盐或盐或化合物的溶剂化物。
• NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
  申请人：Pharmaceutical Co., Ltd. Mochida

  公开号：US20130217690A1

  公开（公告）日：2013-08-22

  [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.

  [目标] 提供一种含有GPR40激动剂的药物，其活性成分为具有GPR40激动剂作用的新化合物、化合物的盐、化合物或盐的溶剂等，特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症或其他疾病的药物。 [解决问题的方法] 化合物I的公式：（其中p为0至4；j为0至2；k为0至1；环A为芳基、杂环基、环烷基、环烯基、螺环基；环B为芳基、杂芳基；X为O或-NR7-；R1至R7和L为特定的基团），化合物的盐或化合物或盐的溶剂。